Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life
Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life
复制标题
DOI：
10.1258/0956462001915020
复制
发表时间：
2000-10-01
影响因子：
1.4
通讯作者：
Frascino, R
中科院分区：
文献类型：
--
作者：
Abrams, DI;Steinhart, C;Frascino, R
为评价依泊替尼对社区HIV感染者生活质量的影响，对221例贫血患者进行了随访。（血红蛋白小于或等于11 g/dl）来自社区治疗中心和医生办公室的艾滋病毒阳性患者接受依泊苷a治疗（100-300单位/kg皮下注射，每周3次），为期4个月，开放标签，非随机，IV期试验。依泊苷α治疗显著（P < 0.01）增加并维持血红蛋白水平（平均增加=2.5 g/dl; n = 207）;血红蛋白水平的改善与CD 4+细胞计数的变化无关。输血需求也从20%显著降低到5%（P < 0.01）。艾滋病感染功能评估量表（FAHI）和身体健康子量表的平均总生活质量评分显著提高（P < 0.05）。与血红蛋白增加相关的QOL改善与CD 4+计数和基线贫血严重程度的变化无关。在依泊苷α治疗期间观察到的不良事件与HIV疾病一致，不太可能由药物引起。应将依泊苷α治疗视为轻度至中度贫血的HIV感染患者的治疗选择。
To evaluate the effect of epoetin alfa on Be quality of life (QOL) of HIV-infected patients in the community setting, 221 anaemic (haemoglobin less than or equal to 11 g/dl) HIV-positive patients from community-based treatment centres and physicians' offices were treated with epoetin alfa (100-300 units/kg subcutaneously 3 times a week) in a 4-month, open-label, non-randomized, phase TV trial. Epoetin alfa therapy significantly (P < 0.01) increased and maintained haemoglobin levels (mean increase=2.5 g/dl; n = 207); the improvement in haemoglobin levels was independent of changes in CD4+ cell counts. Transfusion requirements were also significantly reduced from 20% to 5% of patients (P < 0.01). Mean total QOL score measured by the Functional Assessment of HIV Infection (FAHI) scale and Physical Well-Being subscale score improved significantly (P < 0.05). QOL improvements associated with increases in haemoglobin were independent of changes in CD4+ counts and baseline anaemia severity. Adverse events observed during epoetin alfa therapy were consistent with HIV disease and not likely due to the drug. Epoetin alfa therapy should be considered a treatment option for HIV-infected patients with mild-to-moderate anaemia.